Document:

English Translation of Patent License Agreement dated January 12, 2005

 Exhibit 10.7 
 English Translation 
 Patent License Contract 
 Party A: Mr. Xiaochun Wang (Party A) 
 Party B: Guizhou Tongjitang
Pharmaceutical Co., Ltd. (Party B) 
 After friendly negotiation, party A and party B agree on the following articles about the patent license of toothache
treatment and processing technology: 
  

	1.	Scope of Patent License 

 The license scope of the
patent herein is to manufacture (use and sell) the patent related products in the territory of China, (or) use party A’s patent technology and use and sell the products directly produced according to the patent technology. 
  

	2.	Technology Contents of Patent 

 Party A shall
provide party B with all documents in relation to the patent named after “toothache treatment and processing technology” numbering ZL 95 1 00457.3, and with an international patent primary classification number of
A61K35/78. Moreover, party A shall provide party B with the necessary technology processing documents and relevant technology secrets and other technologies for the implementation of the patent. 
  

	3.	Delivery of Technology Materials 

 Party A shall
deliver to party B all materials stated in Section 2 of this Contract. 
  

	4.	Royalty and Payment 

 The relevant royalty under
this Contract is zero. 
  

	5.	Confidentiality for Know-How 

  

	 	5.1	Party B shall not disclose any patent related know-how to any third party other than the parties herein within the term of and after the termination of this Contract.

  

	 	5.2	Party B shall not replicate the know-how in private, and shall return the know-how to party A after expiration, early termination or amendment of this Contract.

  

	6.	Solution of Infringement 

  

	 	6.1	During the term of this Contract, party A shall assume all legal liabilities if party B is claimed against infringement by any third party. 

  

	 	6.2	In the event that any of the parties discovers that party A’s patent right is infringed by any third party, it shall notify the other party timely. Party A is responsible for
dealing with the infringer, or submitting a claim to the patent authority or filing a suit to the court, and party B is responsible for assistance. 

	7.	Force Majeure 

  

	 	7.1	When there is any event of force majeure beyond both parties’ reasonable control (such as fire, flood, earthquake, warfare, etc.) which prevent the obligations of this contract
from being performed, both parties shall: 

  

	 	7.1.1	Take proper measures to reduce damages; 

  

	 	7.1.2	Notify the other party timely; 

  

	 	7.1.3	Issue the certification of unable to perform the contract during the period of some events; 

  

	 	7.2	The performance shall be delayed within three months after the event of force majeure happens; 

  

	 	7.3	When the event of force majeure continues over three months, this contract will expire. 

  

	8.	Settlement of Disputes 

 When disputes take place
between both parties during the performance of this contract, they shall negotiate friendly in accordance with articles of this contract, and resolve by themselves. 
  

	9.	Effectiveness, Amendment and Termination 

  

	 	9.1	This contract will come into effect after execution by both parties, and the effective term shall be ten years (within validity period of the patent). 

  

	 	9.2	If this contract fails to be performed normally due to party A’s fault, it shall expire, or both parties may otherwise amend relevant articles of this contract.

  

					
	 Party A: /s/ Xiaochun WANG
	 	Party B:	 	(Stamp) Guizhou Tongjitang Pharmaceutical Co., Ltd.
			
		 		 	 Date: January 12, 2005English Translation of Equity Transfer Agreement dated February 20, 2005

 Exhibit 10.8 
 English Translation 
 Equity Transfer Agreement 
 Transferor: Guizhou Tongjitang Pharmaceutical Co., Ltd. (“Tongjitang Pharmaceutical”) 
 Transferee: Mr. Xiaochun Wang 
 Both parties hereby agree to the following, through friendly negotiations, in respect of the
transfer of certain equity interests of Tongjitang Pharmaceutical: 
  

	 	1.	Transferor shall transfer 66.67% of Guizhou Tongjitang Sliced Herbs (the “Company”) held by it to Transferee for RMB3.4 million. 

  

	 	2.	After the transfer is completed, new shareholders of Guizhou Tongjitang Sliced Herbs shall amend the original articles of association and shareholders agreement.

  

	 	3.	Transferee shall assume the credit, indebtedness and other expenses of the Company that arise after the transfer to the extent of his capital contribution to the Company.

  

	 	4.	Prior to the transfer, the Transferor enjoyed the rights and assumed the obligations to the extent of his capital contribution to the Company; after the transfer, Transferor shall
enjoy the rights and assume the obligations of the Company to the extent of its capital contribution to the Company. 

  

	 	5.	This agreement shall be in triplicate with each party holding one counterpart and the third counterpart being filed with the Administration of Industry and Commerce.

  

							
	 Transferor:
	 	(Seal) Guizhou Tongjitang Pharmaceutical Co., Ltd.	 	Transferee:	  	/s/ Xiaochun WANG
		
	 Date: February 20, 2005
	 	Date: February 20, 2005English Translation of Equity Transfer Agreement dated January 18, 2006

 Exhibit 10.9 
 English Translation 
 Equity Transfer Agreement 
  

			
	 Transferor:
	 	Guizhou Tongjitang Pharmaceutical Distribution Co., Ltd. (“Tongjitang Distribution”)
		
	 Transferee:
	 	Mr. Xiaochun Wang [ID no: 510212196802201052]

 Both parties hereby agree to the following, through friendly negotiations, in respect of the transfer of certain
equity interests of Tongjitang Pharmaceutical: 
  

	 	1.	Transferor shall transfer its capital contribution of RMB2.0 million, which represented 33.33% of Guizhou Tongjitang Sliced Herbs, to Transferee for RMB2.0 million.

  

	 	2.	Transferee shall pay RMB2.0 million in full to Transferor within three months after execution of this Agreement. 

  

	 	3.	After the transfer is completed, new shareholders of Guizhou Tongjitang Sliced Herbs (the “Company”) shall amend the original articles of association and
shareholders agreement. 

  

	 	4.	Transferee shall assume the credit, indebtedness and other expenses of the Company that arise after the transfer to the extent of his capital contribution to the Company.

  

	 	5.	Prior to the transfer, the Transferor enjoyed the rights and assumed the obligations to the extent of his capital contribution to the Company; after the transfer, Transferor shall
enjoy the rights and assume the obligations of the Company to the extent of its capital contribution to the Company. 

  

	 	6.	This agreement shall be in triplicate with each party holding one counterpart and the third counterpart being filed with the Administration of Industry and Commerce.

  

					
	Transferor: (Seal)	 	Guizhou Tongjitang Pharmaceutical Distribution Co., Ltd.	 	Transferee: /s/ Xiaochun WANG
		
	Date: January 18, 2006	 	Date: January 18, 2006English Translation of Equity Transfer Contract dated February 20, 2005

 Exhibit 10.10 
 English Translation 
 Equity Transfer Agreement 
  

			
	Transferor:	 	Guizhou Tongjitang Pharmaceutical Co., Ltd. (“Tongjitang Pharmaceutical”)
		
	Transferee:	 	Wang Xiaochun

 Whereas, according to the shareholders resolutions of Tongjitang Pharmaceutical, the Transferor intends to
transfer a 60% equity interest held by the Transferor in Guizhou Tongjitang Culture and Communication Co., Ltd. to Mr. Xiaochun Wang for zero consideration; 
 Now it is agreed as follows: 
  

	 	1.	Transferor shall transfer the 60% equity interest held by it in Guizhou Tongjitang Culture and Communication Co., Ltd. to Mr. Xiaochun Wang for zero consideration and the
Transferee agrees to accept this transfer. 

  

	 	2.	After the Transferee accepts the transfer of the 60% equity interest, the Transferee shall form a new shareholder’s meeting together with Tongfang Honglong (the 25%
shareholder) and Wang Hang (the 15% shareholder), the other two existing shareholders. The new shareholder’s meeting shall amend the incorporation documents of Guizhou Tongjitang Culture and Communication Co., Ltd. 

  

	 	3.	The Transferee shall assume all the credits, indebtedness and other expenses of Guizhou Tongjitang Culture and Communication Co., Ltd. after the transfer in proportion to the
Transferee’s equity interest in Guizhou Tongjitang Culture and Communication Co., Ltd. 

  

	 	4.	Prior to the transfer, the Transferor shall proportionally enjoy the rights and assume the obligations of Guizhou Tongjitang Culture and Communication Co., Ltd.; after the transfer,
the Transferee shall proportionally enjoy rights and assume the obligations. 

  

	 	5.	This transfer agreement shall become effective upon execution by both Transferee and Transferor. 

  

	 	6.	This agreement shall have four original counterparts. Each party shall hold one original counterpart with one filed with Guizhou Tongjitang Culture and Communication Co., Ltd. for
record and the other filed with the relevant administration for industry and commerce. 

  

					
	Transferor: (Seal)	 	Guizhou Tongjitang Pharmaceutical Co., Ltd.	 	Transferee: /s/ Xiaochun WANG
		
	Date: February 20, 2005	 	Date: February 20, 2005Regional Distribution Contract dated September 1, 2006

 Exhibit 10.11 
 English Translation 
 Regional Distribution Contract of 
 Guizhou Tongjitang Pharmaceutical Co., Ltd. 
 Party A:
Guizhou Tongjitang Pharmaceutical Co., Ltd. (hereinafter referred to as “Party A”) 
 Address: 35 Zhengxin Street, Guiyang, Guizhou 
 Legal Representative: Xiaochun WANG 
 Party B: Beijing Shirentang
Pharmaceutical Co., Ltd. (hereinafter referred to as “Party B”) 
 Address: 2A104, 88A Caihuying Street East, Fengtai District, Beijing 

Legal Representative: Mai ZHANG 
 In order to regulate and protect the
distribution market of Party A’s products and protect Party A’s legal interests, based on the cooperation principle of “mutual benefit” and “win-win”, both Parties agreed as follows through friendly consultation:

  

	1.	Party A authorizes Party B to distribute Party A’s products within the following territory: provinces (region, city and county) to the north of the Yellow River including
Beijing. 

  

	2.	Contract Term: One year, from September 1, 2006 to September 30, 2007. Should both Parties want to continue their cooperation upon the expiration of
the Contract Term, they should enter into a separate agreement within 30 days prior to the expiration of the Contract Term; should no separate written agreement be reached, the Contract shall terminate automatically upon the expiration of the
Contract Term. 

  

	3.	Scope of Product: Medicines produced by Party A. 

  

	4.	Distribution Amount: Party B undertakes that, as a regional distributor of Party A, it shall provide Party A with distribution returns not less than RMB90 million during the
year of distribution, and shall achieve half of the distribution returns upon expiration of half of the distribution term. Should Party B fail to achieve the distribution returns as agreed hereunder within the Contract Term, Party A is entitled to
cancel Party B’s qualification as regional distributor. The detailed distribution amount of each period is as follows: 

  

									
	 Time
	  	 Year
 Quarter
	  	 Year
 Quarter
	  	 Year
 Quarter
	  	 Year
 Quarter

	 Distribution Amount
	  	/	  	/	  	/	  	/

  

	5.	Product Price: Party A shall supply products hereunder to Party B at OTC (retailing) supply price; should Party B distribute Party A’s products to OTC retailers (other than the
hospitals listed in hospital retailers) within the territory provided herein, Party A shall provide the supply price to Party B. 

 The following conditions shall be satisfied to apply such price: 
  

	 	1)	Party B must apply 5% off based on the national compulsory wholesale price as the distribution price for distribution of Party A’s products to OTC end retailers;

  

	 	2)	When supplying products to OTC end retailers, Party B shall require the OTC end retailers to sell the products at the price as prescribed by the government; otherwise, Party B is
obliged to cease the supply to such OTC end retailers; 

  

	 	3)	Party B shall provide the computer record of distribution status of the products; 

  

	 	4)	Both Parties shall designate personnel to sign on the records once every month for confirmation. 

  

	 	5)	If Party B distributes the products to other pharmaceutical companies within the distribution territory provided herein, Party A, Party B and such third party must enter into a
separate agreement to specify such hospitals where the products will be distributed in order to settle the payment at the “price for hospital retailers”. Otherwise, it shall be settled at the “price for OTC retailers”.

  

	6.	Return Profits to Outstanding Distributors. 

 At the end of
each year, Party A will return profits to Party B according to Party B’s distribution performance and cooperation, the profits returned shall be 0.5% of the distribution returns. 
 Party B shall not be entitled to get the returned profits, unless all of the following conditions are satisfied: 
  

	 	1)	Party B shall achieve the distribution returns as specified hereunder; 

  

	 	2)	Party B shall actively cooperate with Party A in product promotion; 

  

	 	3)	Party B has never caused the end retailer’s products to be out of stock due to dispatch and allocation reasons; 

  

	 	4)	Party B shall actively cooperate with Party A in sales promotion; 

  

	 	5)	Party B shall observe the Contract and has never distributed trans-territorially; 

  

	 	6)	Party B shall strictly observe the Price Clause as specified hereunder; 

  

	 	7)	Party B shall actively cooperate with Party A in accounting management and issue legal vouchers; 

  

	 	8)	Party B shall timely provide market feedbacks to Party A and propose reasonable suggestions. 

  

 2 

	7.	Delivery and Freight: 

  

	 	1)	Party A shall deliver the products to Party B according to the Products Orders sealed and sent by Party B per fax, letters or other ordering methods; 

  

	 	2)	Party A shall deliver the products to Party B by ways such as postal parcel, and Party A shall bear the freight for the goods to be sent to the city where Party B is located;

  

	 	3)	The place of performance of this Contract is the place where Party A is located. 

  

	8.	Quality, Inspection and Acceptance of Products and the Term to Raise Objection: 

  

	 	1)	Party A undertakes that the products it supplies are in compliance with the relevant quality standards of the government; 

  

	 	2)	Party B shall inspect and accept the products within 24 hours as of the date of the products’ arrival, and Party B shall be liable for the losses incurred due to its failure to
inspect within the time limit; 

  

	 	3)	If Party B discovers that the quality and/or quantity of the goods delivered by Party A are not in compliance with the regulation, it shall submit written objection within three
days after the arrival of the products; if the objection is submitted beyond the time limit, the goods delivered by Party A shall be deemed as in compliance with the provisions hereof. If Party B believes that the products’ quality is not in
compliance with the standards stipulated by the government, it shall present to Party A the Medicine Inspection Report issued by the provincial medicine inspection authority as approved by Party A; 

  

	 	4)	Party A shall reply in writing within 10 days upon receipt of the written objection from Party B; otherwise, the objection by Party B shall be deemed as acknowledged. After Party A
confirms the objection in writing, the products with objection may be returned, exchanged or supplemented; 

  

	 	5)	Party B shall inspect and accept the products timely upon receipt of the invoice issued by Party A, and return the filled out Return Receipt of Invoice to the sales person of Party
A; 

  

	 	6)	Party B shall not lend products to anybody without authorization of Party A; otherwise, Party B shall take all the economic liability incurred thereby. 

  

	9.	Terms of Payment 

  

	 	1)	Party B shall make payment according to the amount of actual distribution. 

  

	 	2)	Discount on the distribution returns: Party B shall return the distribution returns in accordance with the Contract, and Party A may provide the following discount to Party B
according to the term of returns: N/A. 

  

 3 

	 	3)	Party B shall remit the payment into the following account designated by Party A; and Party B shall not remit the payment to any other accounts without authorization of Party A;
otherwise, Party B shall be liable for all the economic losses incurred thereby. The account designated by Party A is: 

 Payee: Guizhou Tongjitang Pharmaceutical Co., Ltd. 
 Account No.: 2402006009007001890 
 Bank: Industrial and Commercial Bank of China, Guizhou Guiyang Branch, Xiaohe Sub-Branch 
  

	10.	Other Rights and Obligations of Both Parties 

  

	 	1)	Party A may launch activities to advertise and promote the products hereunder within Party B’s distribution territory, and may advertise on medium such as TV and newspapers; it
may also organize professional OTC team to make end-promotion and maintenance in order to promote the distribution of the products within Party B’s distribution territory. 

  

	 	2)	Party A may cease the supply of products if it discovers the following acts of Party B, and Party B is obliged to settle the payment with Party A unconditionally and take the
liability for breach of contract: 

  

	 	(1)	Party B distributes trans-territorially; 

  

	 	(2)	Party B fails to confirm the records of distribution status, or prepares false records of distribution status as agreed; 

  

	 	(3)	Party B fails to make payment to Party A timely; 

  

	 	(4)	Party B orders products in the name of the hospitals but the products are actually distributed to OTC markets; 

  

	 	(5)	Party B fails to apply Party A’s price policy; 

  

	 	(6)	Party B fails to timely dispatch products to the end market, which causes the products to be out of stock on the part of retailers; 

  

	 	(7)	Party B fails to cooperate in the relevant work of Party A’s distribution market; 

  

	 	(8)	Part B provides discount sales promotion of Party A’s products without consent or exchange Party A’s products with products of other companies. 

 

	 	3)	In order to maintain the circulation order of the distribution market of the products herein, Party B or its subordinate companies or clients shall not make trans-territorial
distribution; should there be any such trans-territorial distribution, Party A is entitled to order Party B to cease such acts; should Party B or its subordinate companies reject to do so, Party A may terminate the Contract unilaterally.

  

 4 

	 	4)	Party B is obliged to supervise and examine the trans-territorial distribution by its sub-distributors and end-retailers. If such sub-distributors and end-retailers are found to
have distributed products trans-territorially, Party B is obliged to take control measures such as cease of supply. 

  

	 	5)	Party B shall timely prepare the Statement of Production Distribution Status and Statement of Supply, Distribution and Stock of Products, and after affixing its official seal on
such statements, Party B shall submit them to Party A within three days after end of each month. 

  

	 	6)	After receiving the Statements of Account from Party A, Party B shall complete the verification within five days and return them to Party A after affixing the official seal.

  

	 	7)	Party B shall not pay the Payment due in cash to the business representative or other personnel of Party A, nor shall Party B lend such payment to the business representative or
other personnel of Party A. Party A does not acknowledge any of the above acts of Party B and will not take any relevant liability. 

  

	 	8)	Without written consent of Party A, Party B shall not lend or allocate the above products to the business representative or other personnel of Party A. Party A does not acknowledge
any of the above acts of Party B and will not take any relevant liability. 

  

	11.	Liability for Breach of Contract 

  

	 	1)	Party B shall perform the obligation of payment within the term as provided hereunder, and it shall be liable for liquidated damages at 1% of the outstanding amount that it fails to
pay within such term; 

  

	 	2)	In the event of distribution by Party B outside of the prescribed territory herein, Party B shall pay RMB 5000 as the liquidated damages for each such distribution in each
region as we have numbered for the products with a specific batch number. Meanwhile, Party A will cancel the distribution returns of Party B for the whole year. The following shall be determined as trans-territorial distribution: Party B distributes
Party A’s products outside its distribution territory authorized by Party A; or Party B distributes Part A’s products to hospitals within its authorized distribution territory; N/A. 

  

	 	3)	If Party B orders products in the name of hospitals, but actually distributes them to OTC markets, Party A may cancel the distribution returns of Party B for the whole year, and
meanwhile, Party B shall be liable for RMB 5000 liquidated damages. 

  

	 	4)	Both Parties shall perform their respective obligations hereunder, and if the breach of contract of either Party causes economic losses to the other Party, it shall compensate the
other Party for all the losses incurred. 

  

 5 

	12.	Settlement of Disputes 

 Any disputes arising during the
performance hereof shall be resolved by mutual consultations of the both Parties; and the written document produced thereby shall be attached hereto and have the same legal force as this Contract. Should no agreement be reached, either Party may
initiate legal proceeding before the court where it is located. 
  

	13.	The Contract shall take effect upon the signature with official seal by both Parties. 

  

	14.	The Contract is in duplicates, and Party A and Party B shall each hold one copy. 

  

	15.	Supplementary Clause: to be agreed separately by both Parties. 

 Encl. List of Hospitals confirmed by both Parties 
  

			
	 Party A: Guizhou Tongjitang Pharmaceutical Co., Ltd
	  	Party B: Beijing Shirentang Pharmaceutical Co., Ltd
		
	 Address:
	  	Address:
		
	 Zip Code:
	  	Zip Code:
		
	 Legal Representative:
	  	Legal Representative:
		
	 Authorized Representative:
	  	Authorized Representative:
		
	 Name of Operation Manager:
	  	Name of Operation Manager:
		
	 Tel of Operation Manager:
	  	Tel of Operation Manager:
		
	 (official seal)
	  	Name of Financial Manager:
		
		  	Tel of Financial Manager
		
	 [official Seal]
	  	(official seal )
		
		  	[official Seal]
		
	 September 1, 2006
	  	September 1, 2006

  

 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]